Pages that link to "Q33692334"
Jump to navigation
Jump to search
The following pages link to Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. (Q33692334):
Displaying 50 items.
- Imiquimod for anogenital warts in non-immunocompromised adults (Q24188125) (← links)
- Traditional Chinese medicinal herbs for condyloma acuminatum (Q24197808) (← links)
- Advances in the use of topical imiquimod to treat dermatologic disorders (Q24647413) (← links)
- Imiquimod for the treatment of genital warts: a quantitative systematic review (Q24799636) (← links)
- HPV Carcinomas in Immunocompromised Patients (Q26799629) (← links)
- VIN usual type-from the past to the future (Q26865303) (← links)
- Approved Antiviral Drugs over the Past 50 Years (Q27755387) (← links)
- Evolving role of immunotherapy in the treatment of refractory warts (Q28076201) (← links)
- Imiquimod applied topically: a novel immune response modifier and new class of drug (Q28140002) (← links)
- Interferons at age 50: past, current and future impact on biomedicine (Q28259312) (← links)
- Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists (Q33302568) (← links)
- Warts (genital) (Q33448263) (← links)
- Clinical, histopathologic, and molecular aspects of cutaneous human papillomavirus infections (Q33690061) (← links)
- Topical imiquimod: a review of its use in genital warts (Q33726248) (← links)
- An overview of sexually transmitted diseases. Part II. (Q33759589) (← links)
- HPV in the male patient (Q33786349) (← links)
- Immunopathogenesis of haemorrhagic enteritis virus (HEV) in turkeys (Q33862820) (← links)
- Combination treatment with intralesional cidofovir and viral-DNA vaccination cures large cottontail rabbit papillomavirus-induced papillomas and reduces recurrences (Q33981920) (← links)
- Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults (Q34230429) (← links)
- Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment (Q34242591) (← links)
- Signaling by CD40 and its mimics in B cell activation (Q34397107) (← links)
- Immune therapy for human papillomaviruses-related cancers (Q34657561) (← links)
- Human papillomavirus: a review (Q34743451) (← links)
- Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection. (Q35101552) (← links)
- Small Molecule Inhibitors of Human Papillomavirus Protein - Protein Interactions (Q35107717) (← links)
- Local treatment of viral disease using photodynamic therapy (Q35147500) (← links)
- A study on the use of imiquimod for the treatment of genital molluscum contagiosum and genital warts in female patients (Q35199570) (← links)
- Effect of imiquimod on cytokine induction in first trimester trophoblasts (Q35614979) (← links)
- Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream (Q35632513) (← links)
- Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy (Q36373370) (← links)
- Modulation of apoptotic pathways by human papillomaviruses (HPV): mechanisms and implications for therapy. (Q36482809) (← links)
- RNA interference for the treatment of papillomavirus disease. (Q36540664) (← links)
- 3,3'-Diindolylmethane stimulates murine immune function in vitro and in vivo (Q36663538) (← links)
- Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions (Q36967164) (← links)
- TLR-7 activation enhances IL-22-mediated colonization resistance against vancomycin-resistant enterococcus. (Q37190661) (← links)
- The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice (Q37728656) (← links)
- An oral TLR7 agonist is a potent adjuvant of DNA vaccination in transgenic mouse tumor models (Q39920448) (← links)
- Patient-applied treatment for external genital warts: the time has come (Q40322518) (← links)
- Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream (Q41703681) (← links)
- Efficacy and Safety of Imiquimod Versus Podophyllotoxin in the Treatment of Anogenital Warts (Q42678224) (← links)
- Imiquimod-elicited emesis is mediated by the area postrema, but not by direct neuronal activation (Q43698433) (← links)
- Discovery of the first series of inhibitors of human papillomavirus type 11: inhibition of the assembly of the E1-E2-Origin DNA complex (Q44508046) (← links)
- Do we need antivirals for genital herpes simplex virus and human papillomavirus infection? (Q45748704) (← links)
- Prognostic factors and new therapeutic approaches to cervical cancer (Q48557435) (← links)
- Genital warts treatment: Beyond imiquimod. (Q54262209) (← links)
- Warts (genital). (Q55054088) (← links)
- Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of r (Q58605532) (← links)
- Infection with Human Papillomavirus: Update on Epidemiology, Diagnosis, and Treatment (Q73235255) (← links)
- Imiquimod (Q73415890) (← links)
- Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5% (Q78237270) (← links)